Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG for Ovarian Perfusion Assessment
NCT03927651Phase 1Completed
- Sponsor
- Northwestern University
- Start
- Jun 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of indocyanine green in Uterine Fibroids (UF), endometriosis, adenomyosis and 1 more, sponsored by Northwestern University. Primary endpoint: Assessment of ovarian perfusion after ICG administration via fluorescent imaging at 2 years. Started Jun 2019; status: completed.
02
Drugs
indocyanine green
03
Conditions
Uterine Fibroids (UF)endometriosisadenomyosisovarian cyst
Beyond the preview
Go deeper on NCT03927651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927651.